Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | VIR |
---|---|---|
09:32 ET | 7863 | 10.315 |
09:34 ET | 1135 | 10.31 |
09:36 ET | 5280 | 10.45 |
09:38 ET | 600 | 10.5 |
09:39 ET | 1311 | 10.52 |
09:41 ET | 12550 | 10.56 |
09:43 ET | 1400 | 10.56 |
09:45 ET | 2402 | 10.535 |
09:48 ET | 2275 | 10.49 |
09:50 ET | 2999 | 10.43 |
09:52 ET | 700 | 10.43 |
09:54 ET | 1300 | 10.39 |
09:56 ET | 1891 | 10.37 |
09:57 ET | 2601 | 10.35 |
09:59 ET | 1074 | 10.3522 |
10:01 ET | 1700 | 10.3024 |
10:03 ET | 1300 | 10.3 |
10:06 ET | 3103 | 10.2 |
10:08 ET | 800 | 10.205 |
10:10 ET | 1187 | 10.2 |
10:12 ET | 2016 | 10.23 |
10:14 ET | 1599 | 10.2 |
10:15 ET | 2718 | 10.21 |
10:17 ET | 500 | 10.2 |
10:19 ET | 1928 | 10.2341 |
10:21 ET | 400 | 10.245 |
10:24 ET | 1777 | 10.275 |
10:26 ET | 1223 | 10.24 |
10:28 ET | 1500 | 10.25 |
10:30 ET | 490 | 10.24 |
10:32 ET | 1100 | 10.25 |
10:33 ET | 1579 | 10.3 |
10:35 ET | 1000 | 10.285 |
10:37 ET | 1933 | 10.28 |
10:39 ET | 1066 | 10.29 |
10:42 ET | 600 | 10.3 |
10:44 ET | 1900 | 10.27 |
10:46 ET | 700 | 10.26 |
10:48 ET | 3124 | 10.255 |
10:50 ET | 189 | 10.25 |
10:51 ET | 819 | 10.26 |
10:53 ET | 1000 | 10.28 |
10:55 ET | 901 | 10.28 |
10:57 ET | 1200 | 10.33 |
11:00 ET | 1327 | 10.34 |
11:02 ET | 2270 | 10.325 |
11:04 ET | 1500 | 10.3 |
11:06 ET | 1200 | 10.24 |
11:08 ET | 1205 | 10.26 |
11:09 ET | 1301 | 10.26 |
11:11 ET | 2909 | 10.26 |
11:13 ET | 1400 | 10.24 |
11:15 ET | 2559 | 10.2 |
11:18 ET | 900 | 10.23 |
11:20 ET | 100 | 10.23 |
11:22 ET | 2100 | 10.22 |
11:24 ET | 200 | 10.22 |
11:26 ET | 1200 | 10.25 |
11:27 ET | 1150 | 10.25 |
11:29 ET | 1663 | 10.25 |
11:31 ET | 700 | 10.24 |
11:33 ET | 1600 | 10.27 |
11:36 ET | 1400 | 10.25 |
11:38 ET | 1200 | 10.23 |
11:40 ET | 1000 | 10.22 |
11:42 ET | 318 | 10.23 |
11:44 ET | 2226 | 10.23 |
11:45 ET | 700 | 10.22 |
11:47 ET | 902 | 10.235 |
11:49 ET | 1043 | 10.26 |
11:51 ET | 2452 | 10.245 |
11:54 ET | 1200 | 10.24 |
11:56 ET | 1200 | 10.23 |
12:00 ET | 1702 | 10.21 |
12:02 ET | 1723 | 10.22 |
12:03 ET | 1463 | 10.21 |
12:05 ET | 500 | 10.21 |
12:07 ET | 1100 | 10.22 |
12:09 ET | 500 | 10.21 |
12:12 ET | 600 | 10.21 |
12:14 ET | 2243 | 10.225 |
12:16 ET | 1206 | 10.23 |
12:18 ET | 1507 | 10.24 |
12:20 ET | 1200 | 10.26 |
12:21 ET | 1743 | 10.22 |
12:23 ET | 1600 | 10.22 |
12:25 ET | 1435 | 10.22 |
12:27 ET | 989 | 10.24 |
12:30 ET | 1248 | 10.24 |
12:32 ET | 769 | 10.22 |
12:34 ET | 1500 | 10.22 |
12:36 ET | 800 | 10.22 |
12:38 ET | 1701 | 10.22 |
12:39 ET | 708 | 10.23 |
12:41 ET | 600 | 10.21 |
12:43 ET | 2746 | 10.2 |
12:45 ET | 2982 | 10.2 |
12:48 ET | 700 | 10.215 |
12:50 ET | 1100 | 10.215 |
12:52 ET | 1102 | 10.24 |
12:54 ET | 865 | 10.23 |
12:56 ET | 2283 | 10.21 |
12:57 ET | 1000 | 10.22 |
12:59 ET | 600 | 10.205 |
01:01 ET | 800 | 10.21 |
01:03 ET | 1000 | 10.22 |
01:06 ET | 700 | 10.23 |
01:08 ET | 1804 | 10.2 |
01:10 ET | 500 | 10.21 |
01:12 ET | 900 | 10.21 |
01:14 ET | 600 | 10.21 |
01:15 ET | 800 | 10.22 |
01:17 ET | 2584 | 10.21 |
01:19 ET | 400 | 10.2 |
01:21 ET | 600 | 10.21 |
01:24 ET | 1201 | 10.22 |
01:26 ET | 1400 | 10.23 |
01:28 ET | 1275 | 10.245 |
01:30 ET | 1000 | 10.245 |
01:32 ET | 1600 | 10.23 |
01:33 ET | 600 | 10.23 |
01:35 ET | 700 | 10.23 |
01:37 ET | 614 | 10.235 |
01:39 ET | 1000 | 10.235 |
01:42 ET | 1000 | 10.23 |
01:44 ET | 3000 | 10.24 |
01:46 ET | 1100 | 10.26 |
01:48 ET | 600 | 10.27 |
01:50 ET | 1200 | 10.255 |
01:51 ET | 1050 | 10.25 |
01:53 ET | 4243 | 10.21 |
01:55 ET | 1200 | 10.21 |
01:57 ET | 22876 | 10.22 |
02:00 ET | 1600 | 10.23 |
02:02 ET | 800 | 10.24 |
02:04 ET | 1300 | 10.22 |
02:06 ET | 1115 | 10.245 |
02:08 ET | 1500 | 10.255 |
02:09 ET | 572 | 10.265 |
02:11 ET | 2352 | 10.25 |
02:13 ET | 900 | 10.255 |
02:15 ET | 1000 | 10.26 |
02:18 ET | 1300 | 10.285 |
02:20 ET | 2356 | 10.285 |
02:22 ET | 1367 | 10.27 |
02:24 ET | 2198 | 10.28 |
02:26 ET | 1700 | 10.275 |
02:27 ET | 2189 | 10.25 |
02:29 ET | 500 | 10.25 |
02:31 ET | 4420 | 10.25 |
02:33 ET | 800 | 10.255 |
02:36 ET | 1400 | 10.255 |
02:38 ET | 2808 | 10.24 |
02:40 ET | 1786 | 10.23 |
02:42 ET | 1100 | 10.23 |
02:44 ET | 1283 | 10.24 |
02:45 ET | 2380 | 10.245 |
02:47 ET | 2300 | 10.23 |
02:49 ET | 2000 | 10.21 |
02:51 ET | 700 | 10.21 |
02:54 ET | 1200 | 10.21 |
02:56 ET | 922 | 10.22 |
02:58 ET | 1100 | 10.22 |
03:00 ET | 1900 | 10.22 |
03:02 ET | 19092 | 10.21 |
03:03 ET | 1241 | 10.2 |
03:05 ET | 2635 | 10.22 |
03:07 ET | 1800 | 10.24 |
03:09 ET | 598 | 10.24 |
03:12 ET | 1092 | 10.245 |
03:14 ET | 1300 | 10.245 |
03:16 ET | 1300 | 10.24 |
03:18 ET | 1900 | 10.24 |
03:20 ET | 5326 | 10.24 |
03:21 ET | 1427 | 10.21 |
03:23 ET | 2058 | 10.21 |
03:25 ET | 1514 | 10.215 |
03:27 ET | 3386 | 10.225 |
03:30 ET | 8992 | 10.22 |
03:32 ET | 203 | 10.23 |
03:34 ET | 1236 | 10.235 |
03:36 ET | 1300 | 10.25 |
03:38 ET | 300 | 10.25 |
03:39 ET | 700 | 10.245 |
03:41 ET | 5869 | 10.255 |
03:43 ET | 5414 | 10.24 |
03:45 ET | 4001 | 10.24 |
03:48 ET | 3599 | 10.25 |
03:50 ET | 1419 | 10.255 |
03:52 ET | 13653 | 10.305 |
03:54 ET | 3905 | 10.33 |
03:56 ET | 10723 | 10.275 |
03:57 ET | 15713 | 10.26 |
03:59 ET | 9873 | 10.27 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Vir Biotechnology Inc | 1.4B | -2.6x | --- |
Arcus Biosciences Inc | 1.4B | -4.9x | --- |
Immatics NV | 1.1B | -10.4x | --- |
Prothena Corporation PLC | 1.1B | -6.4x | --- |
Protagonist Therapeutics Inc | 1.7B | 11.4x | --- |
Silence Therapeutics PLC | 979.4M | -19.4x | --- |
Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.4B |
---|---|
Revenue (TTM) | $79.6M |
Shares Outstanding | 136.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.49 |
EPS | $-4.01 |
Book Value | $11.80 |
P/E Ratio | -2.6x |
Price/Sales (TTM) | 17.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -780.18% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.